BRAF and melanoma: For example, skin cutaneous melanoma cell lines (SKCM) harbouring BRAF V600E mutations are vulnerable to BRAF kinase inhibitors, and furthermore, this in vitro observation generalises to in vivo models and melanoma patients17.